A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors

Trial Profile

A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Gemcitabine; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 14 Sep 2017 Planned End Date changed from 15 Jun 2017 to 28 Mar 2018.
    • 25 Oct 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2017.
    • 07 Jun 2016 Results evaluating antitumor activity, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top